A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2
740
about 4.6 years
18+
13 sites in CA, CT, FL +8
What this study is about
Researchers are testing a treatment called HER3-DXd for people with advanced solid tumors. The trial will last about 1688 days and enroll approximately 740 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take HER3-DXd
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)
Secondary: Correlation Between HER3 Protein Expression and Efficacy, Disease Control Rate As Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort), Duration of Response As Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort), Overall Number of Participants With Treatment-emergent Adverse Events Following HER3-DXd Monotherapy (All Cohorts), Overall Survival Following HER3-DXd Monotherapy (All Cohorts), Pharmacokinetic Parameter Area Under the Concentration Curve for HER3-DXd (All Cohorts), Pharmacokinetic Parameter Maximum Serum Concentration for HER3-DXd (All Cohorts), Pharmacokinetic Parameter Time to Maximum Serum Concentration for HER3-DXd (All Cohorts)
Oncology